Abstract
Primary or secondary resistance towards conventional chemotherapeutic agents presents the major clinical obstacle in the induction of remission and definite cure of hematological malignancies. Definition of the underlying molecular mechanisms determining response or resistance not only enables the clinician to define prognostic markers, but moreover, facilitates the design of molecularly targeted therapies aiming to reverse the causative lesion and/or the therapeutic resistance. Prostate-apoptosis-response-gene-4 (par-4), which is expressed in a broad spectrum of normal and neoplastic tissues, was originally described in prostate cancer cells forced to undergo apoptosis. In particular, the observation that overexpression of par-4 potentiates apoptosis in malignant cells while sparing normal tissues, renders the assessment of its biological properties and their potential therapeutic exploitation worthwhile. This article focuses on the functional properties of par- 4 in hematopoietic cells, describing their pro-apoptotic and anti-transforming role, and provides an outlook on the potential therapeutical employment of this knowledge.
Keywords: par, chemoresistance, hematopoiesis
Letters in Drug Design & Discovery
Title: Prostate-Apoptosis-Response-Gene-4: Biological Properties and their Potential Therapeutic Exploitation in Hematological Malignancies
Volume: 2 Issue: 4
Author(s): Simone Boehrer, Daniel Nowak, Dieter Hoelzer, Paris S. Mitrou and Kai Uwe Chow
Affiliation:
Keywords: par, chemoresistance, hematopoiesis
Abstract: Primary or secondary resistance towards conventional chemotherapeutic agents presents the major clinical obstacle in the induction of remission and definite cure of hematological malignancies. Definition of the underlying molecular mechanisms determining response or resistance not only enables the clinician to define prognostic markers, but moreover, facilitates the design of molecularly targeted therapies aiming to reverse the causative lesion and/or the therapeutic resistance. Prostate-apoptosis-response-gene-4 (par-4), which is expressed in a broad spectrum of normal and neoplastic tissues, was originally described in prostate cancer cells forced to undergo apoptosis. In particular, the observation that overexpression of par-4 potentiates apoptosis in malignant cells while sparing normal tissues, renders the assessment of its biological properties and their potential therapeutic exploitation worthwhile. This article focuses on the functional properties of par- 4 in hematopoietic cells, describing their pro-apoptotic and anti-transforming role, and provides an outlook on the potential therapeutical employment of this knowledge.
Export Options
About this article
Cite this article as:
Boehrer Simone, Nowak Daniel, Hoelzer Dieter, Mitrou S. Paris and Chow Uwe Kai, Prostate-Apoptosis-Response-Gene-4: Biological Properties and their Potential Therapeutic Exploitation in Hematological Malignancies, Letters in Drug Design & Discovery 2005; 2 (4) . https://dx.doi.org/10.2174/1570180054038350
DOI https://dx.doi.org/10.2174/1570180054038350 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Gene Therapy Strategies Towards Immune Tolerance to Treat the Autoimmune Diseases
Current Gene Therapy NF-κB Inhibitors in Head and Neck Cancer
Letters in Drug Design & Discovery ADCs, as Novel Revolutionary Weapons for Providing a Step Forward in Targeted Therapy of Malignancies
Current Drug Delivery Posaconazole: A New Antifungal Weapon
Reviews on Recent Clinical Trials The Role and Impact of SNPs in Pharmacogenomics and Personalized Medicine
Current Drug Metabolism DNA Hypermethylation of Myeloid Cells, A Novel Therapeutic Target in MDS and AML
Current Pharmaceutical Biotechnology Rheumatologic Manifestations of Hematologic Neoplasms
Current Rheumatology Reviews Targeting Molecular Imaging of Breast Cancer by Radioimmunodetection Method in Nuclear Medicine
Current Molecular Imaging (Discontinued) Effects of Iron Chelation in Osteosarcoma
Current Cancer Drug Targets Targeting Hypoxia for Sensitization of Tumors to Radio- and Chemotherapy
Current Cancer Drug Targets Genetic Variations in Telomere Maintenance, with Implications on Tissue Renewal Capacity and Chronic Disease Pathologies
Current Pharmacogenomics and Personalized Medicine Therapeutic Targeting of CPT-11 Induced Diarrhea: A Case for Prophylaxis
Current Drug Targets Immunotherapeutic Options for Pediatric Malignancies
Current Immunology Reviews (Discontinued) Gene Therapeutic Approaches for Immune Modulation in AIDS
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Imaging Adoptive Cell Transfer Based Cancer Immunotherapy
Current Pharmaceutical Biotechnology Stem Cell Transplant and Idiotypic Vaccination for B-Cell Malignancies
Current Topics in Medicinal Chemistry microRNAs, Gap Junctional Intercellular Communication and Mesenchymal Stem Cells in Breast Cancer Metastasis
Current Cancer Therapy Reviews Matrixmetalloproteinase Inhibitors: Promising Therapeutic Targets Against Cancer
Current Pharmaceutical Design Author Index To Volume 3
Current Topics in Medicinal Chemistry The Impact of Thrombopoietin on Clinical Practice
Current Pharmaceutical Design